The commercial function isn't just marketing. Its critical purpose is to ensure the healthcare delivery system is equipped to receive a new therapy. A great product is merely "table stakes"; adoption hinges on overcoming systemic barriers between regulatory approval and actual patient access.
For a $4.25M gene therapy, commercial success wasn't about convincing payers the price was right, but transparently disclosing the value assessment process. Stakeholders still had "sticker shock" but respected the thoughtful approach, which was a critical win for securing reimbursement and trust.
Instead of focusing solely on quarterly revenue, a successful rare disease launch was measured by KPIs like the number of patients identified and the speed of early intervention. These patient-focused metrics served as leading indicators that ultimately translated into commercial success and a stronger external narrative.
Beren Therapeutics stayed in stealth not just for competitive reasons, but to mend relationships with a patient community fatigued by previous sponsors' failures. This private, focused engagement allowed them to earn trust and protect employees before facing public scrutiny, a strategic use of stealth for community relations.
Many biotechs focus R&D solely on regulatory approval. Beren Therapeutics integrates commercial thinking early to ensure clinical development answers a different question: Is what we're building meaningful to patients, payers, and providers? This de-risks the asset for commercial success, not just clinical milestones.
Beren's founder, with a tech and finance background, leverages his experience as a successful biotech investor to build the company. Rather than follow industry norms, he applies pattern recognition from "a thousand pitches," identifying what made previous management teams and scientific approaches winners, and operationalizes those learnings.